Summary
This prediction ended on 22.09.17 with a price of €16.78. klostergang's SELL prediction for Versartis closed completely unchanged. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Versartis | - | - | - | - |
| iShares Core DAX® | 1.085% | -1.655% | 13.297% | 57.692% |
| iShares Nasdaq 100 | -1.665% | -3.137% | 2.218% | 83.804% |
| iShares Nikkei 225® | 3.863% | 6.947% | 22.818% | 56.282% |
| iShares S&P 500 | 0.111% | -1.320% | 1.445% | 57.791% |
Comments by klostergang for this prediction
In the thread Versartis diskutieren
Versartis' lead candidate VRS-317 flunks late-stage study
Thinly traded small cap Versartis (NASDAQ:VSAR) is set for a tumble after reporting negative results in a Phase 3 clinical trial, VELOCITY, assessing lead candidate somavaratan (VRS-317) for the treatment of pediatric growth hormone deficiency.